Latest Breaking News On - Daniel de boer - Page 1 : comparemela.com

Greenbacker delivers first quarter results

Company announces year-over-year increases in revenue, power production, and operating fleet capacity; completes $437 million financing; and expands.

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutions

Key Insights The considerable ownership by retail investors in ProQR Therapeutics indicates that they collectively have.

Lilly and ProQR Expand RNA Editing Collaboration

ProQR Winds Down Clinical Trials to Focus Exclusively on Axiomer RNA-editing Technology

After RNA therapy falls short in the eye, ProQR Therapeutics pivots to liver, CNS

RNA therapies developer ProQR Therapeutics is eying a future without ophthalmology. After receiving European Medicines Agency feedback for its lead program for a rare eye disorder, the biotech has decided to find a strategic partner for all of its eye drug assets and apply its RNA technology to other therapeutic areas.